Table 2 Primary and secondary outcomes
Variable | Sevoflurane | Control | p-value |
|---|---|---|---|
Primary outcome | n = 28 | n = 32 | |
Primary endpoint reached, n (%) | 11 (16) | 13 (41) | 0.916 |
Death, n (%) | 5 (16) | 5 (18) | 0.817 |
Survivors | n = 23 | n = 27 | |
Persistent organ dysfunction (POD), n (%) | 6 (26) | 8 (30) | 0.781 |
Need of mechanical ventilation | 6 (26) | 8 (30) | 0.781 |
Need of vasopressors | 1 (4) | 7 (26) | 0.028 |
Need of renal replacement therapy | 2 (9) | 4 (15) | 0.502 |
Secondary outcomes | n = 28 | n = 32 | |
Length of stay in ICU, days | 17(± 8) | 17(± 9) | 0.607 |
Length of stay in hospital, days | 23(± 6) | 21(± 7) | 0.808 |
Overall adverse events | 23(82) | 20(63) | 0.088 |
Respiratory failure | 3 (11) | 2 (6) | 0.533 |
Cardiac arrythmia | 7 (25) | 8 (25) | 1.000 |
Congestive heart failure | 1 (4) | 0 | 0.214 |
Acute kidney injury | 11 (39) | 2 (6) | 0.001 |
Acute liver injury | 1 (6) | 3 (9) | 0.356 |
Sepsis | 7 (25) | 4 (13) | 0.211 |
Nosocomial infection | 11 (39) | 12 (38) | 0.887 |
Delirium | 12 (43) | 12 (38) | 0.673 |
Adynamic Ileus | 5 (18) | 1 (3) | 0.050 |
Rhabdomyolysis | 5 (18) | 4 (13) | 0.562 |